#### CONCERT PHARMACEUTICALS, INC.

Form 4

February 21, 2014

| FC | )F | 31 | / 4 | 4 |
|----|----|----|-----|---|
|----|----|----|-----|---|

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**OMB** Washington, D.C. 20549 Number:

if no longer subject to Section 16. Form 4 or Form 5

obligations

Check this box

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

> Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

may continue. See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* **QVT Associates GP LLC** 

2. Issuer Name and Ticker or Trading

5. Relationship of Reporting Person(s) to Issuer

**OMB APPROVAL** 

Expires:

response...

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

Symbol

CONCERT PHARMACEUTICALS,

(Check all applicable)

INC. [CNCE]

(Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)

Director \_X\_\_ 10% Owner Officer (give title \_ Other (specify

02/19/2014

1177 AVENUE OF THE AMERICAS, 9TH FLOOR

> (Street) 4. If Amendment, Date Original

> > Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Form filed by One Reporting Person \_X\_ Form filed by More than One Reporting

Person

below)

NEW YORK, NY 10036

|  |                                      |   |  |   |        |         | 1 CISON  |  |  |
|--|--------------------------------------|---|--|---|--------|---------|--|--|--|
| (City)                                   | (State)                              | (Zip) Tab   | ole I - Non-                           | Derivative S                              | Securi | ties Ac | quired, Disposed   | l of, or Benefi  | icially Owned  |
| 1.Title of<br>Security<br>(Instr. 3)     | 2. Transaction Date (Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3.<br>Transactic<br>Code<br>(Instr. 8) | 4. Securitie on(A) or Disp (Instr. 3, 4 a | osed c | of (D)  | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)    |
|  |                                      |   | Code V                                 | Amount                                    | (D)    | Price   | (Instr. 3 and 4)   |  | Through OVT  |
| Common<br>Stock,<br>\$0.001<br>par value | 02/19/2014                           |   | C                                      | 259,999                                   | A      | (1)     | 259,999  | I  | Through QVT Fund IV LP, QVT Fund V LP and Quintessence Fund L.P. (2) |
| Common Stock, \$0.001 par value (4)      | 02/19/2014                           |   | P                                      | 300,000                                   | A      | \$ 14   | 559,999  | I  | Through QVT<br>Fund IV LP,<br>QVT Fund V<br>LP and<br>Quintessence   |

Fund L.P. (2)

SEC 1474

(9-02)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code<br>(Instr. 8) | 5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                    | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) |                            |
|---|---|---|---|---|---|--|--------------------|---|----------------------------|
|   |   |   |   | Code V                                  | (A) (D)   | Date<br>Exercisable                                      | Expiration<br>Date | Title   | Amount<br>Number<br>Shares |
| Series A<br>Convertible<br>Preferred<br>Stock       | Ш   | 02/19/2014                              |   | С                                       | 250,000   | (1)  | (3)                | Common<br>Stock   | 44,24                      |
| Series B<br>Convertible<br>Preferred<br>Stock       | <u>(1)</u>  | 02/19/2014                              |   | C                                       | 1,000,000   | <u>(1)</u>   | (3)                | Common<br>Stock   | 176,99                     |
| Series C<br>Convertible<br>Preferred<br>Stock       | (1)   | 02/19/2014                              |   | C                                       | 219,000   | <u>(1)</u>   | (3)                | Common<br>Stock   | 38,76                      |

## **Reporting Owners**

| Reporting Owner Name / Address         | Keiationships |           |         |       |  |  |
|--|---------------|-----------|---------|-------|--|--|
| • 9                                    | Director      | 10% Owner | Officer | Other |  |  |
| QVT Associates GP LLC                  |               | X         |         |       |  |  |
| 1177 AVENUE OF THE AMERICAS, 9TH FLOOR |               |           |         |       |  |  |

Reporting Owners 2

Relationshins

#### Edgar Filing: CONCERT PHARMACEUTICALS, INC. - Form 4

NEW YORK, NY 10036

QVT Fund V LP 1177 AVENUE OF THE AMERICAS, 9TH FLOOR X NEW YORK, NY 10036

### **Signatures**

/s/ Tracy Fu, Managing
Member
02/21/2014

\*\*Signature of Reporting Person Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series A, Series B and Series C convertible preferred stock converted into Common Stock on a 1-for-5.65 basis upon the closing of the issuer's initial public offering without payment of consideration.
  - QVT Associates GP LLC is the general partner of QVT Fund IV LP, QVT Fund V LP and Quintessence Fund L.P. (together with QVT Fund IV LP, and QVT Fund V LP, the "Funds"). QVT Financial LP is the investment manager for the Funds and therefore may be
- (2) deemed the beneficial owner of the Common Stock held by the Funds. QVT Financial GP LLC is the general partner of QVT Financial LP and therefore may be deemed the beneficial owner of Common Stock beneficially owned by QVT Financial LP. The reporting person disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.
- (3) Not applicable.
- (4) These 300,000 shares were purchased by the Funds in the Issuer's initial public offering, at which time the reporting persons were no longer 10% owners or otherwise subject to Section 16.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3